Dr. Michelle McMurry-Heath will become BIO’s President and CEO on June 1, 2020

After a comprehensive search, the Biotechnology Innovation Organization (BIO) has announced that Michelle McMurry-Heath, MD, PhD, as its incoming President and CEO.  McMurry-Heath will become the organization’s next President and CEO on June 1, 2020. 

BIO is the world’s largest science and public advocacy organization, representing 1,000 members.  McMurry-Heath will succeed former Rep. Jim Greenwood, who has led the organization since 2005 and BIO’s founding President & CEO Carl B. Feldbaum who served from 1993 to  2004.Continue reading

Biotechnology Innovation Organization Launches New Medicine Pipeline Tracker Illustrates Unprecedented Effort to Eradicate COVID-19

Washington, DC (May 12, 2020) – The Biotechnology Innovation Organization (BIO) today unveiled a first-of-its-kind, interactive tracker of the new treatments and vaccines in the COVID-19 pipeline. This online resource illustrates the unprecedented campaign being undertaken by biopharmaceutical innovators to combat – and ultimately eradicate – the novel coronavirus. Continue reading

AdvaMed Issues MedTech Compliance Guidance For COVID-19 Response

WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today announced availability of a newly created “Code of Ethics Compliance Guidance Related to the COVID-19 Response.”

“This guidance seeks to help AdvaMed members and other medical technology companies develop and implement processes that both support rapid decision-making in the context of the pandemic and mitigate any related compliance risks,” said Christopher L. White, AdvaMed COVID action team leader, chief operating officer and general counsel.Continue reading